We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$8.38B
AUM Growth
+$319M
Cap. Flow
-$50.3M
Cap. Flow %
-0.6%
Top 10 Hldgs %
33.94%
Holding
161
New
20
Increased
28
Reduced
35
Closed
14

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$304M
2
ELV icon
Elevance Health
ELV
+$123M
3
XRAY icon
Dentsply Sirona
XRAY
+$102M
4
AGN
Allergan plc
AGN
+$95.1M
5
INSP icon
Inspire Medical Systems
INSP
+$78.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$185M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$154M
3
ABBV icon
AbbVie
ABBV
+$145M
4
THC icon
Tenet Healthcare
THC
+$119M
5
BMY icon
Bristol-Myers Squibb
BMY
+$69.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.69%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
101
Rocket Pharmaceuticals
RCKT
$337M
$15.2M 0.18%
775,000
– –
AMED
102
DELISTED
Amedisys
AMED
$14.6M 0.17%
171,100
-36,400
-18% -$2.67M
NBRV
103
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$13.6M 0.16%
15,678
– –
NBIX icon
104
Neurocrine Biosciences
NBIX
$18.2B
$13.5M 0.16%
137,800
+62,800
+84% +$5.62M
THC icon
105
Tenet Healthcare
THC
$22.2B
$12.5M 0.15%
372,900
-3,816,400
-91% -$119M
GTS
106
DELISTED
Triple-S Management Corporation
GTS
$11.4M 0.14%
305,662
-289,265
-49% -$9.14M
WMGIZ
107
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$11.2M 0.13%
8,746,583
– –
NVTA
108
DELISTED
Invitae Corporation
NVTA
$11.2M 0.13%
1,518,197
– –
PRQR icon
109
ProQR Therapeutics
PRQR
$246M
$9.51M 0.11%
1,302,955
– –
DERM
110
DELISTED
Dermira, Inc.
DERM
$9.49M 0.11%
+1,031,596
New +$9.62M
LAB icon
111
Standard BioTools
LAB
$318M
$9.44M 0.11%
1,583,700
– –
ALXN
112
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$8.69M 0.1%
70,000
+20,000
+40% +$2.34M
ATNX
113
DELISTED
Athenex, Inc. Common Stock
ATNX
$8.02M 0.1%
21,500
– –
DBVT
114
DBV Technologies
DBVT
$806M
$7.92M 0.09%
41,070
– –
ADAP
115
DELISTED
Adaptimmune Therapeutics
ADAP
$7.91M 0.09%
666,593
-200,000
-23% -$2.49M
BMRN icon
116
BioMarin Pharmaceuticals
BMRN
$12B
$7.21M 0.09%
76,500
-69,000
-47% -$6.04M
TECX
117
Tectonic Therapeutic
TECX
$553M
$7.14M 0.09%
+20,833
New +$7.52M
XFOR icon
118
X4 Pharmaceuticals
XFOR
$376M
$6.78M 0.08%
10,383
– –
BMRN icon
119
CALL
BioMarin Pharmaceuticals
BMRN
$12B
$6.59M 0.08%
+70,000
New +$6.13M
ECOR icon
120
electroCore
ECOR
$51.4M
$6.57M 0.08%
+26,548
New +$7.21M
ALKS icon
121
Alkermes
ALKS
$8.31B
$5.97M 0.07%
145,000
– –
XENE icon
122
Xenon Pharmaceuticals
XENE
$6.26B
$5.84M 0.07%
634,812
– –
RARE icon
123
Ultragenyx Pharmaceutical
RARE
$2.52B
$5.2M 0.06%
+67,605
New +$4.37M
RDHL
124
Redhill Biopharma
RDHL
$4.26M
$4.82M 0.06%
565
– –
CLVS
125
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$4.55M 0.05%
100,000
+35,000
+54% +$1.7M
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2018 Portfolio in Review

As of Q2 2018, OrbiMed held 161 positions worth $8.38B, up 4% from $8.07B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q2 2018 filing shows 20 new, 28 increased, 35 reduced and 14 closed positions. Its largest new stake was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M. The largest sale was Regeneron Pharmaceuticals, an estimated $185M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 94% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2018 buy was Tricida, Inc. Common Stock: 10,889,280 shares worth $326M.
  • OrbiMed added most to Dentsply Sirona in Q2 2018, an estimated $102M increase.
  • OrbiMed's biggest Q2 2018 reduction was Regeneron Pharmaceuticals, cutting an estimated $185M.
  • OrbiMed fully exited ARMO BioSciences, Inc. Common Stock in Q2 2018, selling an estimated $154M.
  • OrbiMed's ten largest holdings make up 34% of its $8.38B portfolio in Q2 2018.
  • OrbiMed opened 20 new positions and closed 14 in Q2 2018.
  • OrbiMed's portfolio value rose 4% quarter-over-quarter to $8.38B.

Based on OrbiMed's 13F filing for Q2 2018, filed 14 Aug 2018.